<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>13</volume><submitter>Debus JL</submitter><pubmed_abstract>&lt;h4>Background&lt;/h4>Multiple sclerosis (MS) is the most common immune-mediated demyelinating disease in younger adults. Patients with MS (PwMS) are vulnerable to the presence of potential drug-drug interactions (pDDIs) and potential drug-food interactions (pDFIs) as they take numerous medications to treat MS, associated symptoms and comorbidities. Knowledge about pDDIs and pDFIs can increase treatment success and reduce side effects.&lt;h4>Objective&lt;/h4>We aimed at determining the frequency and severity of pDDIs and pDFIs in PwMS, with regard to polypharmacy.&lt;h4>Methods&lt;/h4>In the cross-sectional study, we analysed pDDIs and pDFIs of 627 PwMS aged ⩾18 years. Data collection was performed through patient record reviews, clinical examinations and structured patient interviews. pDDIs and pDFIs we</pubmed_abstract><journal>Therapeutic advances in chronic disease</journal><pagination>20406223221108391</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9358348</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Associated factors of potential drug-drug interactions and drug-food interactions in patients with multiple sclerosis.</pubmed_title><pmcid>PMC9358348</pmcid><pubmed_authors>Zettl UK</pubmed_authors><pubmed_authors>Hecker M</pubmed_authors><pubmed_authors>Baldt J</pubmed_authors><pubmed_authors>Debus JL</pubmed_authors><pubmed_authors>Langhorst SE</pubmed_authors><pubmed_authors>Streckenbach B</pubmed_authors><pubmed_authors>Mashhadiakbar P</pubmed_authors><pubmed_authors>Bachmann P</pubmed_authors><pubmed_authors>Frahm N</pubmed_authors><pubmed_authors>Heidler F</pubmed_authors></additional><is_claimable>false</is_claimable><name>Associated factors of potential drug-drug interactions and drug-food interactions in patients with multiple sclerosis.</name><description>&lt;h4>Background&lt;/h4>Multiple sclerosis (MS) is the most common immune-mediated demyelinating disease in younger adults. Patients with MS (PwMS) are vulnerable to the presence of potential drug-drug interactions (pDDIs) and potential drug-food interactions (pDFIs) as they take numerous medications to treat MS, associated symptoms and comorbidities. Knowledge about pDDIs and pDFIs can increase treatment success and reduce side effects.&lt;h4>Objective&lt;/h4>We aimed at determining the frequency and severity of pDDIs and pDFIs in PwMS, with regard to polypharmacy.&lt;h4>Methods&lt;/h4>In the cross-sectional study, we analysed pDDIs and pDFIs of 627 PwMS aged ⩾18 years. Data collection was performed through patient record reviews, clinical examinations and structured patient interviews. pDDIs and pDFIs we</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022</publication><modification>2025-04-04T19:27:35.558Z</modification><creation>2025-02-19T01:57:06.17Z</creation></dates><accession>S-EPMC9358348</accession><cross_references><pubmed>35959503</pubmed><doi>10.1177/20406223221108391</doi></cross_references></HashMap>